Today CYTENA, a BICO company, launched C.STATION, a new platform for fully automated stable cell line development. The platform combines CYTENA’s already proven single cell dispensing technology along with its best-in-class liquid handling expertise to enable affordable and high-quality laboratory automation. This combination of technologies advances BICO’s Bio Convergence agenda and democratizes access to production of next generation healthcare solutions including antibody therapies, gene therapies, and biosimilar production.   

C.STATION is a key step in advancing the Bio Convergence revolution by combining several proven technologies, cell cultures, and smart software to produce monoclonal antibodies and viral vectors for gene therapy,” explained Dr. Julian Riba, CEO of CYTENA. “I could not be more proud of our team for their work on this incredible platform and am excited to bring this to our already hundreds of existing customers working on cell line development.

The C.STATION covers the entire cell line development workflow from single-cell cloning of transfected cells to selecting high-producing clones and upscaling. By integrating proven technologies and protocols into a user-friendly platform, the C.STATION will democratize laboratory automation in this important healthcare field. Using the platform, thousands of clones can be isolated, screened, and selected for upscaling with minimal user interaction. Since the work cell relies on standard well plates it can be readily integrated into existing lab infrastructure.

Along with cell line development, CYTENA develops award-winning products across liquid handling, single cell dispensing, bioreactors, live cell analysis, and NGS reagents. Its devices are used in labs by leading life science organizations that include AstraZeneca, Bayer, Genentech, Sanofi, Novo Nordisk, GlaxoSmithKline, Novartis, the National Institutes of Health, Merck, Bristol-Myers Squibb, Amgen, and others.

Companies and organizations interested in the C.STATION can find more information at cytena.com.

For further information, please contact:
Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70 830 0890
Email:
il@bico.com    

BICO Press office 
Phone (US):
Riley Munks, PR Manager: (650) 863-6699
Alyssa D’Orazio, PR Manager: (617) 634-9601
Email: press@bico.com

This information was submitted for publication, through the agency of the contact persons set out above, on October 19, 2021, at 3pm (CEST).

About CYTENA

CYTENA is a leading provider of high-precision instruments for isolating, dispensing, imaging, analyzing and handling biological cells, and continues to build on the success of the single-cell dispensing technology the company patented as a spin-off from the University of Freiburg, Germany, in 2014. Today, as part of BICO, the world’s leading bioconvergence company, CYTENA’s award-winning devices are still manufactured in Germany and used at prestigious academic and pharmaceutical labs around the world to automate workflows in numerous application areas, including stable cell line development, single-cell omics, high-throughput screening and drug discovery. CYTENA’s breakthrough innovations for the lab combine advanced automation, state-of-the-art software engineering and the latest insights in cell biology to maximize efficiencies in the life sciences and create the future of health. Learn more at www.cytena.com

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.

With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.

The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com